The Conversation (0)
Swedish Orphan Biovitrum today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development.
Swedish Orphan Biovitrum AB (publ) (https://www.sobi.com/) (Sobi™) (STO: SOBI) today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development (R&D).
Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity.
“We are delighted to welcome Milan to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Milan brings a creative global translational and development profile which can build and expand upon our strong legacy of biologics innovation.”
Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle development, focusing on advancing and expanding Sobi’s early and mid-stage pipeline under a unified innovation strategy. “I am looking forward to joining the team at Sobi and to advancing Sobi’s mission to develop and deliver innovative therapies to people with rare diseases,” said Milan. Milan will join Sobi on 1 November 2016.
– – – About Sobi™
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more information please contact Media relations Investor relations Linda Holmström, Sr Jörgen Winroth, Vice Communications Manager President, Head of Investor Relations T: + 46 708 73 40 95, + 46 T: +1 347-224-0819, +1 212 8 697 31 74 -579-0506, +46 8 697 2135 linda.holmstrom@sobi.com jorgen.winroth@sobi.com The above information was released for public distribution on 26 September 2016, at 08:00 CET. Swedish Orphan Biovitrum AB Postal address SE-112 76 Stockholm, Sweden Phone: +46 8 697 20 00 www.sobi.com
Swedish Orphan Biovitrum AB
Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity.
“We are delighted to welcome Milan to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Milan brings a creative global translational and development profile which can build and expand upon our strong legacy of biologics innovation.”
Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle development, focusing on advancing and expanding Sobi’s early and mid-stage pipeline under a unified innovation strategy. “I am looking forward to joining the team at Sobi and to advancing Sobi’s mission to develop and deliver innovative therapies to people with rare diseases,” said Milan. Milan will join Sobi on 1 November 2016.
– – – About Sobi™
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more information please contact Media relations Investor relations Linda Holmström, Sr Jörgen Winroth, Vice Communications Manager President, Head of Investor Relations T: + 46 708 73 40 95, + 46 T: +1 347-224-0819, +1 212 8 697 31 74 -579-0506, +46 8 697 2135 linda.holmstrom@sobi.com jorgen.winroth@sobi.com The above information was released for public distribution on 26 September 2016, at 08:00 CET. Swedish Orphan Biovitrum AB Postal address SE-112 76 Stockholm, Sweden Phone: +46 8 697 20 00 www.sobi.com
Swedish Orphan Biovitrum AB
